DE vs PFE: Which Is the Better Buy?
Side-by-side comparison of Deere & Company and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-09.
Deere & Company · Industrials
$596.74
-29.8% upside to fair value
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DE |
PFE |
| Current Price |
$596.74 |
$25.22 |
| Fair Value Estimate |
$418.72 |
$25.92 |
| Upside to Fair Value |
-29.8%
|
+2.8%
|
| Market Cap |
$161.1B |
$143.7B |
| Forward P/E |
33.7x
|
19.2x
|
| EV / EBITDA |
19.0x
|
12.3x
|
| Price / Sales |
3.4x
|
2.3x
|
| Price / FCF |
42.8x
|
15.2x
|
| Revenue Growth YoY |
+6.7%
|
+5.4%
|
| Gross Margin |
35.4%
|
69.3%
|
| Operating Margin |
18.4%
|
23.4%
|
| Return on Equity |
18.3%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.34%
|
6.6%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Deere & Company operates in the agricultural machinery sector, providing durable equipment critical to farming and construction industries. The business quality is high, supported by a strong 18.3% return on equity and solid gross and operating margins of 35.4% and 18.4%, respectively. However, the stock is currently overvalued, trading approximately 30% above its fair value estimate of $418.72, …
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
DE |
PFE |
| Zone Low |
$314.04 |
$19.44 |
| Zone High |
$355.91 |
$22.03 |
| In Buy Zone? |
No
|
No
|